Chapter 4 70 SUPPLEMENTARY MATERIAL This Supplementary Material provides more background information regarding the redaction of estimates of cost, Quality-Adjusted Life Years (QALYs) and Incremental Cost-Effectiveness Ratio’s (ICERs) available in Technology Appraisals (TAs) as available from the National Institute of Care and Excellence (NICE) in the United Kingdom. Part A: Overview of redacted appraisals Supplementary table 1: Overview of redacted technology appraisals by disease area Estimate Redacted Disease area Yes, N = 811 No, N = 1841 Overall, N = 265 Oncology 35 (37%) 59 (63%) 94 Hematology 22 (45%) 27 (55%) 49 Neurology 4 (27%) 11 (73%) 15 Ophthalmology 4 (29%) 10 (71%) 14 Rheumatology 5 (36%) 9 (64%) 14 Gastroenterology 2 (18%) 9 (82%) 11 Cardiology 0 (0%) 10 (100%) 10 Dermatology 3 (30%) 7 (70%) 10 Vascular medicine 0 (0%) 10 (100%) 10 Endocrinology 0 (0%) 8 (100%) 8 Infectious diseases 0 (0%) 8 (100%) 8 Pulmonology 2 (29%) 5 (71%) 7 Benign hematology 1 (25%) 3 (75%) 4 Psychiatry 0 (0%) 4 (100%) 4 Internal medicine 2 (67%) 1 (33%) 3 Nephrology 0 (0%) 2 (100%) 2 Urology 1 (50%) 1 (50%) 2 1n (%)
RkJQdWJsaXNoZXIy MTk4NDMw